Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANV419 + daratumumab
- Development stage
- Unknown
- Lead developer
- Anaveon
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**ANV419 + daratumumab** is a combination therapy under investigation for the treatment of relapsed/refractory multiple myeloma. ANV419 is an engineered, IL-2Rb-selective agonist—an antibody-IL-2 fusion protein designed to deliver high-dose interleukin-2 (IL-2) preferentially to natural killer (NK) and CD8+ cytotoxic T cells, thereby enhancing anti-tumor immunity. Daratumumab is a monoclonal antibody that selectively targets CD38, a glycoprotein highly expressed on myeloma cells, causing their death via mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct apoptosis. Preclinical studies indicate that ANV419 increases NK cell activation and, when combined with daratumumab, significantly enhances NK cell-mediated killing of myeloma cells via ADCC. The combination is being evaluated in the OMNIA-2 Phase I/II clinical trial for relapsed/refractory multiple myeloma[1][3][5][7].
- Other names
- DarzalexANV419 + daratumumab
02
Targets
IL2RB (IL-2 receptor beta chain)CD38 (Cluster of Differentiation 38)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on ANV419 + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANV419 + daratumumab.